_This book discusses new candidates for rapid-acting antidepressants, such as (R)-ketamine, (2R,6R)-hydroxynorketamine, scopolamine, mGluR2/3 antagonists and AMPA receptor agonists. There are serious limitations to currently available antidepressants, such as delayed onset and low rates of efficacy. The discovery that a single dose of ketamine, an NMDAR antagonist, can produce rapid antidepressant effects that are sustained has led to new research in this area. In this volume, a variety of novel pharmaceutical treatments are examined. This volume would be useful to both researchers and clinicians who work in the field of pharmacology, specifically CNS drug treatments.
Anmelden
| ISBN | 9783030797904 |
|---|---|
| Artikelnummer | 9783030797904 |
| Medientyp | E-Book - PDF |
| Copyrightjahr | 2021 |
| Verlag | Springer-Verlag |
| Umfang | 149 Seiten |
| Kopierschutz | Digitales Wasserzeichen |
